Question 1

What is SELLAS Life Sciences Group, Inc.'s proceeds from issuance of common stock, common stock warrants, and pre-funded warrants, net of issuance costs?

Accepted Answer

SELLAS Life Sciences Group, Inc. (SLS) reported proceeds from issuance of common stock, common stock warrants, and pre-funded warrants, net of issuance costs of $0 in Q1 2026.

Question 2

How has SELLAS Life Sciences Group, Inc.'s proceeds from issuance of common stock, common stock warrants, and pre-funded warrants, net of issuance costs changed year-over-year?

Accepted Answer

SELLAS Life Sciences Group, Inc.'s proceeds from issuance of common stock, common stock warrants, and pre-funded warrants, net of issuance costs decreased by 100.0% year-over-year, from $23.03M to $0.

Question 3

What does proceeds from issuance of common stock, common stock warrants, and pre-funded warrants, net of issuance costs mean?

Accepted Answer

This metric captures the net cash proceeds received from the combined issuance of common stock and associated warrants, after accounting for issuance costs. It reflects the total capital raised through equity-linked financing rounds. Investors use this to evaluate the company's success in securing funding to support clinical development and operational runway.

SELLAS Life Sciences Group, Inc. SLS Proceeds from issuance of common stock, common stock warrants, and pre-funded warrants, net of issuance costs

Proceeds from issuance of common stock, common stock warrants, and pre-funded warrants, net of issuance costs at other companies

Other financials

Income statement

Balance sheet

Cash flow

Valuation

Profitability

Returns & leverage

Where this comes from

Ask your AI about SELLAS Life Sciences Group, Inc.'s proceeds from issuance of common stock, common stock warrants, and pre-funded warrants, net of issuance costs.

Questions, answered.